IsoPlexis Partners with MediMergent and The Center for Cancer and Blood Disorders in Study of AZD7442 for Prevention of COVID-19 Infection in Immuno-Compromised Cancer Patients
2022年9月6日 - 8:00PM
IsoPlexis (NASDAQ: ISO), a company empowering labs to
leverage the cells and proteome changing the course of human
health, today announced a partnership with MediMergent, LLC, and
The Center for Cancer and Blood Disorders (CCBD), an American
Oncology Partners of Maryland practice, to leverage IsoPlexis’
single-cell proteomics in a large multi-site study of
immuno-compromised cancer patients. The study entitled “Real World
Evaluation of the Effectiveness of AZD7442 for Prevention of
COVID-19 Infection in Immuno-Suppressed Cancer Patients”, will
focus on immune cells’ functionality and their role in prevention
of COVID-19 breakthrough infections in immuno-compromised patients,
following administration of AZD7442 IM or IV. IsoPlexis' platform
uniquely reveals highly active cells capable of secreting multiple
cytokines simultaneously. The company’s single-cell proteomics
technology enables researchers to identify these highly powerful
single cells which correlate with immune response, therapeutic
persistence, and disease outcomes. In partnership with MediMergent,
which designs and deploys programs to collect Real-World Evidence
used for regulatory submission and product commercialization, and
CCBD, a leading community oncology practice with locations in
Bethesda and Germantown, Maryland, IsoPlexis will enable
researchers to uncover T cell activity and mechanisms associated
with COVID-19 breakthrough infections in immuno-compromised cancer
patients.
"Through our partnership with MediMergent and CCBD,
we hope to advance scientists’ understanding of the mechanisms of
breakthrough COVID-19 infections in high-risk immuno-compromised
cancer populations, and the potential role of highly-active cells
and T cell polyfunctionality," said IsoPlexis Chief Executive
Officer, Sean Mackay. "We are excited to align with
MediMergent and CCBD in their mission to give a voice to diverse
patient populations and address issues surrounding the COVID-19
pandemic including vaccine hesitancy and
resistance.”
“We are very excited to be able to measure not just
B-cell function and antibody titers, but also T-cell function. This
should allow us to correlate how different patients have different
incidences of infection and how these T-cell measurements might
shed light on differences in severity of infection,” noted Ralph
Boccia, MD, FACP, Principal Investigator of the study.
“Understanding the different impacts of COVID-19
breakthrough infections is vital to developing better treatments
for immuno-compromised patients, and we’re glad to be working with
IsoPlexis to conduct this study,” said Bruce Garrett, MD, Chief
Operating Officer at MediMergent. “We are looking forward to
extracting new real-world evidence that will empower patients and
aid in designing better therapeutics to fight the global COVID-19
pandemic.”
About IsoPlexis: IsoPlexis is
empowering labs, changing the course of human health. Its systems
uniquely identify a comprehensive range of multifunctional single
cells, i.e. the superhero cells in the human body. These cells
enable researchers to understand and predict disease progression,
treatment resistance and therapeutic efficacy to advance all of
human health. IsoPlexis has been named Top Innovation or Design by
The Scientist Magazine, Fierce, BIG Innovation, Red Dot and
multiple others. The IsoPlexis platform is used globally by
researchers, including those at the top 15 global pharmaceutical
companies and over two-thirds of leading U.S. comprehensive cancer
centers. IsoPlexis systems are for research use only and not for
use in diagnostic procedures.
About MediMergent: MediMergent,
LLC is a data collection, integration and analytics company that
utilizes its proprietary platform to implement customized, patient
centric, real-world evidence projects for health care companies to
support their commercial interests and regulators to better
understand real-world patient safety and medication
effectiveness.
About The Center for Cancer and Blood
Disorders: (CCBDMD.com)Specialists in the diagnosis and
treatment of blood disorders and cancer, The Center for Cancer and
Blood Disorders has been serving patients in the communities
and surrounding areas of Bethesda and Germantown,
Maryland for more than 25 years. Their individualized approach
to patient care includes chemotherapy, targeted therapy,
immunotherapy and when appropriate, cutting-edge therapies on
clinical trials. The practice regularly performs more than 300
clinical trials on new and developing diagnostic devices and
techniques for cancer and other diseases. Patients have access to
in-house lab and pathology, specialty pharmacy and on-site infusion
therapy. The practice also offers comprehensive support with
nutrition guidance and financial counseling.
Cautionary Note Regarding Forward Looking
StatementsCertain statements in this press release are
forward-looking statements that are subject to risks and
uncertainties that could cause results to be materially different
than expectations. Such statements can be identified by the use of
words such as "will", "signal", "confident", "potential", "forward"
and "bring". Important factors that could cause actual results to
differ materially include: the rate of adoption of the Company's
technology by its customers and potential customers as well as the
risk factors set forth in the Risk Factors section of the Company's
prospectus filed with the SEC. These forward-looking statements are
not guarantees of future performance and speak only as of the date
hereof, and, except as required by law, IsoPlexis disclaims any
obligation to update these forward-looking statements to reflect
future events or circumstances.
Investor
Contactinvestors@isoplexis.com
Press
Contactpress@isoplexis.com
Related Linkswww.isoplexis.com
SOURCE IsoPlexis
IsoPlexis (NASDAQ:ISO)
過去 株価チャート
から 8 2024 まで 9 2024
IsoPlexis (NASDAQ:ISO)
過去 株価チャート
から 9 2023 まで 9 2024